madman
Super Moderator
* Recent advances in understanding the dysregulation of phosphodiesterase type 5 (PDE5) have led to novel therapeutic approaches, including using PDE5 inhibitors in a counterintuitive but effective manner. He shares a landmark clinical trial in Nigeria that demonstrates a 58% reduction in priapism episodes with a combination of hydroxyurea and tadalafil, offering a promising long-term strategy for those with sickle cell disease.
Arthur L. Burnett II, MD, MBA, FACS, focuses on priapism. In this 26-minute presentation, Dr. Burnett explores the pathophysiology, management strategies, and evolving treatment paradigms for this condition, particularly in patients with sickle cell disease.
Dr. Burnett highlights that surgical interventions, including shunting techniques and penile prosthesis implantation, remain critical options, with variable success. Recent advances in understanding the dysregulation of phosphodiesterase type 5 (PDE5) have led to novel therapeutic approaches, including using PDE5 inhibitors in a counterintuitive but effective manner. He shares a landmark clinical trial in Nigeria that demonstrates a 58% reduction in priapism episodes with a combination of hydroxyurea and tadalafil, offering a promising long-term strategy for those with sickle cell disease.
Dr. Burnett underscores the importance of clinical guidelines, translational research, and global collaborations to improve outcomes. Future directions focus on refining treatment algorithms and enhancing patient education to reduce the burden of this distressing condition.
Arthur L. Burnett II, MD, MBA, FACS, focuses on priapism. In this 26-minute presentation, Dr. Burnett explores the pathophysiology, management strategies, and evolving treatment paradigms for this condition, particularly in patients with sickle cell disease.
Dr. Burnett highlights that surgical interventions, including shunting techniques and penile prosthesis implantation, remain critical options, with variable success. Recent advances in understanding the dysregulation of phosphodiesterase type 5 (PDE5) have led to novel therapeutic approaches, including using PDE5 inhibitors in a counterintuitive but effective manner. He shares a landmark clinical trial in Nigeria that demonstrates a 58% reduction in priapism episodes with a combination of hydroxyurea and tadalafil, offering a promising long-term strategy for those with sickle cell disease.
Dr. Burnett underscores the importance of clinical guidelines, translational research, and global collaborations to improve outcomes. Future directions focus on refining treatment algorithms and enhancing patient education to reduce the burden of this distressing condition.
